Siren LLC’s enGene Therapeutics ENGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$35.8M Buy
5,253,159
+1,916,895
+57% +$17.1M 0.99% 30
2025
Q4
$30.1M Buy
+3,336,264
New +$26.7M 0.9% 32

Other funds holding ENGN

Siren LLC's ENGN Position: Q1 2026 in Review

Siren LLC increased its enGene Therapeutics (ENGN) stake by 57% in Q1 2026, buying an estimated $17.1M and bringing the position to 5,253,159 shares worth $35.8M. The position accounts for 0.99% of the portfolio, ranked #30.

Siren LLC first reported a position in ENGN in Q4 2025 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Siren LLC held 5,253,159 shares of enGene Therapeutics worth $35.8M as of Q1 2026.
  • Siren LLC bought 1,916,895 enGene Therapeutics shares in Q1 2026, an estimated $17.1M.
  • enGene Therapeutics made up 0.99% of Siren LLC's portfolio in Q1 2026, its #30 holding.
  • Siren LLC first reported a position in enGene Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Siren LLC's 13F filing for Q1 2026, filed 14 May 2026.